Resultado de búsqueda
View Brian Abrahams’ profile on LinkedIn, a professional community of 1 billion members. As a biotechnology equity research analyst, I am passionate about understanding and…
Dr. Brian Abrahams joined RBC Capital Markets in July 2017 as a senior analyst covering the biotechnology sector. He has 15 years of experience following large, mid, and small cap biotech companies, and prior to RBC spent time in biotechnology equity research at Jefferies, Wells Fargo, and CIBC World Markets / Oppenheimer & Co.
Dr. Brian Abrahams joined RBC Capital Markets in July 2017 as a senior analyst covering the biotechnology sector. He has 18 years of experience following large, mid, and small cap biotech companies, and prior to RBC spent time in biotechnology equity research at Jefferies, Wells Fargo, and CIBC World Markets / Oppenheimer & Co.
24 de sept. de 2021 · What are the disruptors and drivers that are affecting the biotech market? On the latest Industries in Motion podcast, RBC Capital Markets Co-Head of Biotechnology Research Brian Abrahams reveals the headwinds and tailwinds, and why he believes biotech’s 2021 lows are about to end.
Brian Abrahams is a 4.43-star Wall Street Analyst at RBC Capital. Brian Abrahams's focuses on the Healthcare sector and covers 111 stocks with a 49.39% success rate.
214,101 followers. 1w. We are proud to share that RBC Capital Markets' Biotechnology team again ranked in Institutional Investor 's 2023 All-America Research Team Survey. Congratulations to all...
316. Total ratings. 52.78% Success rate. 9.15% Average return. Main Sectors: Healthcare. Top Industries: Biotechnology Drug Manufacturers - General Drug Manufacturers - Specialty & Generic. 30 Stocks. Brian Abrahams is a Wall Street analyst working for RBC Capital.
